Literature DB >> 14625469

Contrast agents for magnetic resonance imaging: safety update.

Miles A Kirchin1, Val M Runge.   

Abstract

Magnetic resonance contrast agents, particularly the gadolinium-based agents, are extremely safe and lack the nephrotoxicity associated with iodinated contrast media. Currently, seven gadolinium agents are available in one or more countries of the world, of which only four are available for clinical use in the United States. Minor adverse effects associated with each of these agents occur infrequently and include nausea, headache, and taste perversion. Whereas the gadolinium agents cannot be differentiated on the basis of these mild adverse effects, recent studies have brought to light the issue of chelate stability, and in particular, clinical observations associated with the least stable of these agents. This review briefly discusses the most recent safety issues concerning the gadolinium agents. A brief review of safety issues concerning the non-gadolinium agents is also provided.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625469     DOI: 10.1097/00002142-200310000-00007

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  24 in total

1.  High-resolution MR lymphangiography for planning lymphaticovenous anastomosis treatment: a single-centre experience.

Authors:  Maria Antonietta Mazzei; Francesco Gentili; Francesco Giuseppe Mazzei; Paolo Gennaro; Duccio Guerrieri; Andrea Nigri; Guido Gabriele; Elisabetta Weber; Alfonso Fausto; Giuseppe Botta; Luca Volterrani
Journal:  Radiol Med       Date:  2017-08-02       Impact factor: 3.469

Review 2.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

Review 3.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

4.  MR-lymphangiography at 3.0 T--a feasibility study.

Authors:  Mike Notohamiprodjo; Ruediger G H Baumeister; Tobias F Jakobs; Kerstin U Bauner; Holger F Boehm; Annie Horng; Maximilian F Reiser; Christian Glaser; Karin A Herrmann
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

Review 5.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

6.  Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Authors:  Z Seidl; J Vymazal; M Mechl; M Goyal; M Herman; C Colosimo; M Pasowicz; R Yeung; B Paraniak-Gieszczyk; B Yemen; N Anzalone; A Citterio; G Schneider; S Bastianello; J Ruscalleda
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

Review 7.  [Ultrasound contrast agents. Pharmaceutical drug safety and bioeffects].

Authors:  M Krix; J W Jenne
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

8.  Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T.

Authors:  Ulrike I Attenberger; Henrik J Michaely; Bernd J Wintersperger; Steven P Sourbron; Klaus-Peter Lodemann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Eur Radiol       Date:  2008-02-16       Impact factor: 5.315

9.  Which patients with dilated common bile and/or pancreatic ducts have positive findings on EUS?

Authors:  Vernon Carriere; Jason Conway; Jerry Evans; Susanne Shokoohi; Girish Mishra
Journal:  J Interv Gastroenterol       Date:  2012-10-01

Review 10.  Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors:  Hale Ersoy; Frank J Rybicki
Journal:  J Magn Reson Imaging       Date:  2007-11       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.